Attached files
file | filename |
---|---|
EX-4.1 - EX-4.1 - SELLAS Life Sciences Group, Inc. | b86049exv4w1.htm |
EX-99.1 - EX-99.1 - SELLAS Life Sciences Group, Inc. | b86049exv99w1.htm |
8-K - 8-K - SELLAS Life Sciences Group, Inc. | b86049e8vk.htm |
EX-5.1 - EX-5.1 - SELLAS Life Sciences Group, Inc. | b86049exv5w1.htm |
EX-1.1 - EX-1.1 - SELLAS Life Sciences Group, Inc. | b86049exv1w1.htm |
Exhibit 99.2
RXi Pharmaceuticals Prices $12 Million Public Offering
of Common Stock and Warrants
WORCESTER, Mass., April 15, 2011 (BUSINESS WIRE) RXi Pharmaceuticals Corporation (Nasdaq:
RXII), a biotechnology company focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using immunotherapy and RNA-targeted technologies,
today announced that it has priced an underwritten public offering of 11,950,000 units at a price
to the public of $1.00 per unit for gross proceeds of approximately $12 million. Each unit
consists of one share of common stock and a warrant to purchase one share of common stock at an
exercise price of $1.00 per share. The shares of common stock and warrants are immediately
separable and will be issued separately such that no units will be issued. The warrants are
exercisable beginning one year and one day from the date of issuance, but only if RXiss
stockholders approve an increase in the number of its authorized shares of common stock, and expire
on the sixth anniversary of the date of issuance. Net proceeds, after underwriting discounts and
commissions and other estimated fees and expenses payable by RXi, and assuming the warrants are not
exercised, will be approximately $10.9 million. RXi intends to use the net proceeds of the offering
for general corporate purposes, which may include working capital, capital expenditures, research
and development expenditures, clinical and pre-clinical trial expenditures, commercial
expenditures, acquisitions of new technologies or businesses that are complementary to its current
technologies or business focus, and investments. The offering is expected
to close on or about April 20, 2011, subject to satisfaction of customary closing conditions. ROTH
Capital Partners, LLC is acting as the sole manager for the offering.
The securities described above are being offered by RXi Pharmaceuticals pursuant to a shelf
registration statement on Form S-3 including a base prospectus, previously filed and declared
effective by the Securities and Exchange Commission (SEC). The securities may be offered only by
means of a prospectus. A preliminary prospectus supplement related to the offering was filed with
the SEC on April 14, 2011 and a final prospectus supplement related to the offering will be filed
with the SEC today.
Electronic copies of the final prospectus supplement, when available, may be
obtained by either contacting the underwriter (as set forth below) or by accessing the SECs
website, www.sec.gov.
Roth Capital Partners, LLC
Attn: Syndicate Department
24 Corporate Plaza
Newport Beach, CA 92660
Phone: (800) 678-9147
Email: Rothecm@roth.com
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any
securities of RXi Pharmaceuticals Corporation, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering,
developing and commercializing innovative therapies addressing major unmet medical needs using
RNA-targeted and immunotherapy technologies. For more information, visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
the Apthera acquisition, future expectations, plan and future development of RXis and Aptheras
products and technologies. These forward-looking statements about future expectations, plans and
prospects of the development of RXis and Aptheras products and technologies involve significant
risks, uncertainties and assumptions, including the risk that the development of NeuVax or our
RNAi-based therapeutics may be delayed or may not proceed as planned and we may not be able to
complete development of any RNAi-based product, the risk that the reduction in our early stage RNAi
research and development activities may adversely affect our ability to effectively develop our
RNAi technologies, to develop
existing or new RNAi product candidates or to enter into or
effectively continue collaborations or strategic alliances in this field, the risk that the FDA
approval process may be delayed for any drugs that we develop, risks related to development and
commercialization of products by our competitors, risks related to our ability to control the
timing and terms of collaborations with third parties and the possibility that other companies or
organizations may assert patent rights that prevent us from developing our products. Actual results
may differ materially from those RXi contemplated by these forward-looking statements. RXi does not
undertake to update any of these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Contacts
RXi Pharmaceuticals
Tamara McGrillen, 508-929-3615
ir@rxipharma.com
or
Investors
S. A. Noonan Communications
Susan Noonan, 212-966-3650
susan@sanoonan.com
or
Media
Rx Communications Group
Eric Goldman, 917-322-2563
egoldman@rxir.com